HIV Vaccine Market Opportunity & Clinical Pipeline Analysis

Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become one of the greatest challenges of public health facing all countries of the world. According to UNAIDS, death due to AIDS was estimated to close to 1.6 million in 2012. There were 2.3 million new HIV infections, and about 35.3 million people currently living with HIV. Given the pace at which the HIV virus is spreading, it is most likely that AIDS would take more lives than any other infectious disease in the future years to come. Inspite of well-expanded programs of prevention and treatment which are currently enabling the stakeholders to address the illness and death associated with HIV and AIDS, the HIV vaccines is considered to be the best solution to end this disease successfully.

HIV/AIDS has become of the leading infectious disease which is taking a huge death toll across the globe, even surpassing TB and malaria. Irrespective of whether the country is developed or developing, the disease is increasingly becoming prevalent, though with serious impact in the developing countries. It has been observed that almost nine out of every ten HIV infections are being diagnosed in the developing countries, and two-thirds are in Sub-Saharan Africa. India currently has close to 4 million infected people, which is the largest number of infected persons of any country in the world. Despite of the combating efforts, the Asian and other developing regions are increasingly feeling the heat as HIV continues to spread at a significant rate.

Download Report:

https://www.kuickresearch.com/report-HIV-Vaccine-Market-Opportunity-&-Clinical-Pipeline-Analysis.php

In recent years there have been significant breakthroughs achieved in terms of prevention and treatment of HIV/AIDS. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and an efficient vaccine, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future.

It is expected that in the next 5-8 years, the pharmaceutical companies would focus more on the development of a successful efficient vaccine to control the spread of this disease. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. There needs to be complete scrutiny of every single technological area of HIV prevention R&D so as to reflect the best methods of channelizing the funds which are limited in nature. The funds need to be specifically directed towards only those products and approaches which have a high probability of succeeding, instead of those which are less promising.

“HIV Vaccine Market Opportunity & Clinical Pipeline Analysis” Report Highlights:

* Introduction to HIV Vaccine & Mechanism
* Global HIV Incidence Scenario
* R&D Funding Scenario for HIV Vaccine
* FDA Regulatory Framework
* HIV Vaccine Clinical Trial by Phase & Country
* HIV Vaccines in Development Phase: More Than 100
* Most HIV Vaccines in Preclinical Phase: More Than 50
* Discontinued & Suspended HIV Vaccines Profiles

For Report Sample Contact: neeraj@kuickresearch.com or

visit: https://www.kuickresearch.com

Recent Publications:

* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.